Table 5. Dosage Adjustment and Monitoring in Patients Developing Aminotransferase Abnormalities⁵

ALT/AST levels	Dosage recommendations
> 3 and < 5 x ULN	Confirm and reduce daily dose or interrupt treatment. Monitor ALT/AST every 2 weeks. If levels return to pretreatment levels, continue or reintroduce treatment at starting dose.
> 5 and < 8 x ULN	If confirmed, stop treatment. Monitor ALT/AST every 2 weeks. If levels return to pretreatment levels, reintroduce treatment at starting dose.
> 8 x ULN	Stop treatment. Reintroduction should not be considered.

ULN: Upper Limit of Normal

 

Return to article